Crossmark

High-Efficiency Transduction of Primary Human Hematopoietic Stem/Progenitor Cells by AAV6 Vectors: Strategies for Overcoming Donor-Variation and Implications in Genome Editing

Crossref DOI link: https://doi.org/10.1038/srep35495

Published Online: 2016-10-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ling, Chen

Bhukhai, Kanit

Yin, Zifei

Tan, Mengqun

Yoder, Mervin C.

Leboulch, Philippe

Payen, Emmanuel

Srivastava, Arun
License Information

Text and Data Mining valid from 2016-10-19

Version of Record valid from 2016-10-19
More Information

Article History

Received: 23 May 2016

Accepted: 30 September 2016

First Online: 19 October 2016

Competing interests

: A.S. holds issued patents related to AAV vectors that have been licensed to various AAV gene therapy companies. P.L. and E.P. have financial relationships with bluebird bio, Inc. All other authors declare no competing interests.

Document is current

Any future updates will be listed below